Top 5 Drug Type | Count |
---|---|
Small molecule drug | 6 |
Monoclonal antibody | 1 |
Target |
Mechanism IL-31RA inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. JP |
First Approval Date28 Mar 2022 |
Target |
Mechanism RARγ agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date04 Oct 2019 |
Target |
Mechanism RARs agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date08 Dec 2008 |
Start Date01 Jan 2023 |
Sponsor / Collaborator |
Start Date11 Aug 2022 |
Sponsor / Collaborator |
Start Date20 Jul 2022 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Adapalene ( RARs ) | Acne Vulgaris More | Approved |
Trifarotene ( RARγ ) | Acne Vulgaris More | Approved |
Amorolfine Hydrochloride ( Ergosterol x SQLE ) | Skin Diseases, Infectious More | Approved |
Adapalene/Benzoyl Peroxide ( RARs ) | Acne Vulgaris More | Approved |
Methyl Aminolevulinate Hydrochloride | Basal Cell Carcinoma More | Approved |